Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 28;9(10):FSO897.
doi: 10.2144/fsoa-2023-0108. eCollection 2023 Dec.

Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer

Kehinde S Okunade  1   2   3 , Sarah O John-Olabode  4 , Adaiah P Soibi-Harry  2 , Austin C Okoro  2 , Adebola A Adejimi  5 , Iyabo Y Ademuyiwa  6 , Benedetto Osunwusi  2 , Hameed Adelabu  3 , Omolola Salako  7
Affiliations

Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer

Kehinde S Okunade et al. Future Sci OA. .

Abstract

Purpose: This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria.

Methods: We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested.

Results: Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99).

Conclusion: These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC.

Keywords: Africa; EOC; SII; ovarian cancer; overall survival; prognosis; progression-free survival.

Plain language summary

This study looked at how the systemic immune-inflammation index (SII) can predict the outcomes of patients with epithelial ovarian cancer (EOC). To do this, the data of 91 women who received treatment for EOC between 2009 and 2018 were analyzed. The study concluded that when the SII level was higher than 610.2 and 649.0, it was linked to a higher likelihood of EOC progressing sooner and of reduced survival at the 3-year mark, respectively. This suggests that a high SII might be a useful predictor to understand how EOC could progress and how well patients with EOC might survive.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.. The receiver operating characteristic curve for progression-free survival.
Showing an area under the curve of 0.65 (95% CI: 0.52–0.78), a sensitivity of 71.4% and a specificity of 61.9%.
Figure 2.
Figure 2.. The receiver operating characteristic curve for 3-year overall survival.
Showing an area under the curve of 0.62 (95% CI: 0.50–0.74), a sensitivity of 60.0% and a specificity of 69.6%
Figure 3.
Figure 3.. The Kaplan–Meier survival curve of progression-free survival.
Stratified by the SII cut-off values – SII >610.2 x 109 cells/L was significantly associated with a shorter progression-free survival in epithelial ovarian cancer patients (p = 0.006).
Figure 4.
Figure 4.. The Kaplan–Meier survival curve of 3-year overall survival.
Stratified by the SII cut-off values – SII >649.2 x 109 cells/l was significantly associated with a shorter overall survival in epithelial ovarian cancer patients (p = 0.009).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021). - PubMed
    1. Okunade KS, Ugwu AO, Soibi-Harry AP et al. Pattern of gynaecological malignancies at a university teaching hospital In Southwest Nigeria: a 5-year review. Niger. Med. J. 63(2), 127–132 (2023). - PMC - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023). - PubMed
    1. Okunade KS, Dawodu O, Adenekan M et al. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer. Niger. J. Clin. Pract. 23, 1141–1147 (2020). - PMC - PubMed
    1. Okunade KS, Adejimi AA, Ohazurike EO et al. Predictors of survival outcomes after primary treatment of epithelial ovarian cancer in Lagos, Nigeria. JCO Glob. Oncol. 7, 89–98 (2021). - PMC - PubMed

LinkOut - more resources